The metastasis status and tumor burden-associated CA125 level combined with the CD4/CD8 ratio predicts the prognosis of patients with advanced pancreatic cancer: A new scoring system
The metastasis status and tumor burden-associated CA125 level combined with the CD4/CD8 ratio predicts the prognosis of patients with advanced pancreatic cancer: A new scoring system
复制标题
DOI：
10.1016/j.ejso.2017.07.010
复制
发表时间：
2017-11-01
期刊：
影响因子：
3.8
通讯作者：
Liu, C.
中科院分区：
文献类型：
--
作者：
Yang, C.;Cheng, H.;Liu, C.
简介：尽管据报道 CA125 和肿瘤免疫反应与胰腺癌相关，但它们对于接受化疗的晚期胰腺癌患者的预后价值仍不确定。因此，我们研究了CA125水平与CD4/CD8比值组合的预后价值。方法：在排除失访或缺少完整临床数据的患者后，最终对369名参与者进行了检查。采用Cox风险模型进行单因素和多因素分析，并采用Kaplan-Meier法和时序检验进行生存率比较。结果：单因素和多因素分析显示，高CA125水平和高CD4/CD8比值是独立的预后因素（CA125>=35 U/ml，风险比（HR）= 1.90，p < 0.001；CD4/CD8 >= 1.8，HR = 1.37，p = 0.004）。此外，将CA125水平与CD4/CD8比值结合形成新的评分系统后，HR显着升高（CA125>=35U/ml且CD4/CD8>=1.8，得分2，HR=2.76，95%置信区间：2.04至3.74，p<0.001）。结论：基于CA125水平与CD4/CD8比值相结合的新评分系统CD4/CD8比值可以进一步预测晚期胰腺癌患者的预后。 (C) 2017 Elsevier Ltd、BASO（类似于癌症手术协会）和欧洲肿瘤外科学会。版权所有。
Introduction: Although CA125 and the tumor immune response have been reported to be associated with pancreatic cancer, their prognostic value for advanced pancreatic cancer patients undergoing chemotherapy remain uncertain. We thus studied the prognostic value of the combination of the CA125 level with the CD4/CD8 ratio.Methods: After excluding patients who were lost to follow-up or for whom complete clinical data were missing, 369 participants were ultimately examined. Univariate and multivariate analyses were performed using the Cox hazards model, and Kaplan-Meier methods and log-rank tests were used for the comparison of survival rates.Results: Univariate and multivariate analyses showed that a-high CA125 level and a high CD4/CD8 ratio were independent prognostic factors (CA125 >= 35 U/ml, Hazard Ratio (HR) = 1.90, p < 0.001; CD4/CD8 >= 1.8, HR = 1.37, p = 0.004). Moreover, after combining the CA125 level and CD4/CD8 ratio to form a new scoring system, the HR was substantially elevated (CA125 >= 35 U/ml and CD4/CD8 >= 1.8, score 2, HR = 2.76, 95% confidence interval: 2.04 to 3.74, p < 0.001).Conclusions: A new scoring system based on the combination of the CA125 level with the CD4/CD8 ratio could further predict the prognosis of patients with advanced pancreatic cancer. (C) 2017 Elsevier Ltd, BASO similar to The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights reserved.